We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Sangamo Announces Expansion of Research Collaboration Agreement with Pfizer

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Sangamo BioSciences, Inc. has announced that it has entered into a second agreement with Pfizer Inc that expands the scope of existing research collaboration in the field of enhanced protein production.

Under the terms of the agreement, Pfizer will fund further research at Sangamo and Sangamo will use its zinc finger DNA-binding protein (ZFP) technology to develop additional cell lines for enhanced protein production.

"Over the past year we have enjoyed a very productive collaboration with Pfizer, the world's leading research-based pharmaceutical company," said Edward Lanphier, Sangamo's president and chief executive officer.

"We believe that the expansion of this agreement is evidence of our successful development and application of this technology to facilitate the generation of improved production cell lines with altered traits."

By engineering ZFPs that recognize a specific DNA sequence Sangamo scientists have created ZFP transcription factors (ZFP TFs™) that can control gene expression and consequently, cell function.

Sangamo is also developing sequence-specific ZFP nucleases (ZFNs™) for targeted gene correction, gene disruption and gene insertion.